The effects of Primidone in human pregnancy and nursing infants are unknown. There is evidence in mothers treated with primidone that the drug appears in breast milk in substantial quantities. Since tests for the presence of primidone in biological fluids are too complex to be carried out in the average clinical laboratory, it is suggested that the presence of undue somnolence and drowsiness in nursing newborns of Primidone-treated mothers be taken as an indication that nursing should be discontinued.
The total daily dosage should not exceed 2 g. Since Primidone therapy generally extends over prolonged periods, a complete blood count and a sequential multiple analysis-12 (SMA-12) test should be made every 6 months.
Adjunct anti-epileptic drugs
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
